Biopharmaceutical company UCB (EBR:UCB) announced on Wednesday new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondylarthritis (axSpA), which includes both non-radiographic axial spondylarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitis (AS).

The company says that BIMZELX, a dual inhibitor of IL-17A and IL-17F, demonstrated sustained control of inflammation and deep efficacy in patients living with PsA and axSpA,2-5 chronic inflammatory diseases with considerable impact on physical and emotional wellbeing.

Across the three-year clinical trial data for PsA and axSpA, BIMZELX was generally well-tolerated and no new safety signals were observed. The most common treatment-emergent adverse events (TEAEs) over three years for both PsA and axSpA in these studies were SARS-CoV-2 (COVID-19) infection, nasopharyngitis, and upper respiratory tract infection.

UCB is presenting 14 abstracts on PsA and axSpA at EULAR 2025 in Barcelona, Spain, from 11-14 June, and will complement other presentations from UCB in systemic lupus erythematosus and osteoporosis.